Innovative Eyewear (NASDAQ:LUCY – Get Free Report) and Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.
Institutional & Insider Ownership
1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 1.7% of Innovative Eyewear shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for Innovative Eyewear and Cellectar Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Innovative Eyewear | 1 | 1 | 0 | 0 | 1.50 |
| Cellectar Biosciences | 1 | 0 | 3 | 0 | 2.50 |
Valuation and Earnings
This table compares Innovative Eyewear and Cellectar Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Innovative Eyewear | $2.66 million | 1.83 | -$7.59 million | ($1.69) | -0.45 |
| Cellectar Biosciences | N/A | N/A | -$21.79 million | ($6.66) | -0.42 |
Innovative Eyewear has higher revenue and earnings than Cellectar Biosciences. Innovative Eyewear is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Innovative Eyewear and Cellectar Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Innovative Eyewear | -272.42% | -83.37% | -76.02% |
| Cellectar Biosciences | N/A | -349.24% | -153.18% |
Risk and Volatility
Innovative Eyewear has a beta of 2.71, meaning that its stock price is 171% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
Summary
Cellectar Biosciences beats Innovative Eyewear on 7 of the 13 factors compared between the two stocks.
About Innovative Eyewear
Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Receive News & Ratings for Innovative Eyewear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovative Eyewear and related companies with MarketBeat.com's FREE daily email newsletter.
